Stock Price & Analysis

Based on the provided data, here's a concise analysis of DHR stock:

Technical Analysis The stock is currently trading at $238.36, showing bearish signals with RSI at 53.83 indicating neutral momentum. The stock is trading above its 20-day moving average of $233.77, suggesting short-term upward momentum despite recent pressure.

Recent Events DHR stock has been impacted by new export controls on biotechnology equipment. The stock dropped 1.7% following the U.S. Commerce Department's announcement of restrictions targeting biotech equipment exports to China, affecting the entire biotech sector.

Analyst Sentiment Recent analyst actions show mixed but generally positive sentiment:

• Citigroup maintains Strong Buy with $285 target (19.65% upside)
• B of A Securities upgraded to Strong Buy with $290 target
• Wolfe Research upgraded to Buy with $285 target

Technical Levels Key Fibonacci levels:

• Resistance: R1 at $242.13, R2 at $245.34
• Support: S1 at $231.75, S2 at $228.54
• Pivot point: $236.94

Based on technical analysis and recent developments, selling DHR at current levels is recommended as the stock faces headwinds from new export controls and shows technical weakness in the short term.

Based on the provided data and context, here's a comprehensive analysis for DHR's stock price prediction in 2025:

Technical Analysis

Current Market Position The stock is currently trading at $238.36, showing a decline of 1.46% in the last regular trading session. The stock has been trading in a range between $238.17 and $243.05 on January 17, 2025, with relatively moderate volume of 3.07M shares.

Price Prediction Analysis

Based on recent market data and analyst forecasts, here's the 2025 price prediction for DHR:

The stock is expected to reach $291.30 by end of 2025, representing a potential upside of 27.8% from current levels. This prediction is supported by:

1. Strong Analyst Consensus: Out of 21 analysts covering DHR, 14 rate it as "Strong Buy" and 2 as "Moderate Buy", indicating strong institutional confidence in the stock's future performance.

2. Growth Catalysts: The healthcare sector, where DHR primarily operates, is expected to generate 21% earnings growth in 2025, which should positively impact DHR's performance.

3. Recent Headwinds Resolution: While DHR faced challenges in Q4 2024 with projected low-single-digit declines in adjusted core sales, the company's strong market position and continuous improvement through its Danaher Business System (DBS) are expected to drive recovery in 2025.

Specific Price Target: $291.30 by end of 2025

• Primary reason: Strong analyst consensus and healthcare sector's robust growth outlook
• Supporting factor: Expected recovery in core sales and margin improvement

The S1 support level for DHR Stock is $234.29 ,The R1 resistant level for DHR Stock is $246.13.

As of the end of day on 2025-01-24, the price of DHR Stock was $245.8.

The target price for DHR Stock according to analyst rating is 283.12, with the highest price target at 315.00 and the lowest at 255.00. Analysts have a Moderate Buy rating on DHR Stock overall.

The market cap of DHR is $177.5B.

Based on the provided data, I'll analyze whether DHR is overvalued in 5 concise sentences:

DHR currently trades at a P/E of 51.9x (Q3 2024), which is significantly higher than its historical average and appears stretched compared to industry peers. The company's declining net income trend (from $1.088B in Q1 2024 to $818M in Q3 2024) and deteriorating net margin (from 18.77% to 14.11%) raise concerns about its premium valuation. While recent analyst ratings show mixed sentiment with a median price target of $285 (implying ~19% upside), the declining gross margins and stagnant revenue growth suggest the current valuation multiple may be difficult to justify. The biotech export controls announced by the U.S. Commerce Department have created additional headwinds for DHR's business outlook. Given these factors and the company's rich valuation metrics (EV/EBITDA of 29.47x), DHR appears to be overvalued at current levels.

Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.

Based on the provided data and market analysis, here is the price prediction for DHR stock by 2030:

Danaher stock is projected to reach $380-400 by 2030, driven by its strong positioning in life sciences and diagnostics sectors after spinning off its Environmental & Applied Solutions business into Veralto in late 2023. The company's focus on biotechnology, life sciences and diagnostics segments that have favorable secular growth trends and high recurring revenue characteristics supports this bullish outlook.

The recent export controls on biotechnology equipment to China may create some near-term headwinds, but Danaher's diversified portfolio and strong market position in critical healthcare technologies should help drive sustained growth over the long term.

DHR has a total of 61000 employees.